|
|
Volumn 114, Issue 3, 2004, Pages 688-689
|
|
The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BIOLOGICAL MARKER;
BUDESONIDE;
HLA DP ANTIGEN;
HLA DPB1 ANTIGEN;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
MONTELUKAST;
SHORT ACTING DRUG;
UNCLASSIFIED DRUG;
ANTIASTHMATIC AGENT;
HLA DPB1;
HLA-DPB1;
ADULT;
ASTHMA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG TOLERANCE;
EXPIRATORY FLOW;
FEMALE;
GENOTYPE;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
NOSE POLYP;
PREDICTION;
PRIORITY JOURNAL;
RHINOSINUSITIS;
TREATMENT WITHDRAWAL;
DRUG HYPERSENSITIVITY;
GENETIC MARKER;
GENETICS;
MIDDLE AGED;
PREDICTION AND FORECASTING;
ADULT;
ANTI-ASTHMATIC AGENTS;
ASPIRIN;
ASTHMA;
DRUG HYPERSENSITIVITY;
FEMALE;
GENETIC MARKERS;
HLA-DP ANTIGENS;
HUMANS;
LEUKOTRIENE ANTAGONISTS;
MALE;
MIDDLE AGED;
PREDICTIVE VALUE OF TESTS;
|
|
EID: 4444353625
PISSN: 00916749
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jaci.2004.05.051 Document Type: Letter |
|
Times cited : (29)
|
|
References (8)
|
